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Abstract
The mast/stem cell growth factor receptor KIT has long been assumed to be a specific marker for interstitial cells of Cajal (ICC) in the bladder,
with possible druggable perspectives. However, several authors have challenged the presence of KIT+ ICC in recent years. The aim of this study
was therefore to attempt to clarify the conflicting reports on KIT expression in the bladder of human beings, rat, mouse and guinea pig and to
elucidate the possible role of antibody-related issues and interspecies differences in this matter. Fresh samples were obtained from human, rat,
mouse and guinea pig cystectomies and processed for single/double immunohistochemistry/immunofluorescence. Specific antibodies against
KIT, mast cell tryptase (MCT), anoctamin-1 (ANO1) and vimentin were used to characterize the cell types expressing KIT. Gut (jejunum) tissue
was used as an external antibody control. Our results revealed KIT expression on mast cells but not on ICC in human, rat, mouse and guinea
pig bladder. Parallel immunohistochemistry showed KIT expression on ICC in human, rat, mouse and guinea pig gut, which confirmed the selec-
tivity of the KIT antibody clones. In conclusion, we have shown that KIT+ cells in human, rat, mouse and guinea pig bladder are mast cells and
not ICC. The present report is important as it opposes the idea that KIT+ ICC are present in bladder. In this perspective, functional concepts of
KIT+ ICC being involved in sensory and/or motor aspects of bladder physiology should be revised.
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Introduction
There is a general consensus in the literature that the bladder con-
tains two populations of stromal or interstitial cells (IC): IC in the
lamina propria [1–3] (LP) (i.e. the area between the urothelium and
detrusor smooth muscle) and IC in the detrusor [4] (inter- and
intramuscular). Having been reported in bladders from different
species including rat [5], guinea pig [4, 6], mouse [7] and human
beings [8], these two IC populations appear to be a constant, spe-
cies-independent finding. Functional data on bladder IC are still
limited, and the general hypothesis is that LP IC might be involved
in non-neural sensory signal transduction from the urothelium
towards the detrusor muscle, while detrusor IC might have a role
in pacemaking and/or transduction of pacemaking signals in the
detrusor area [3].
One of the major research topics for bladder IC has been the
search for specific cell markers. Of the several markers reported in
the literature, the mast/stem cell growth factor receptor KIT (also
known as the proto-oncogene c-kit or CD117) is one of the most
extensively studied ones. KIT is a tyrosine-protein kinase which acts
as a cell-surface receptor for the cytokine KIT ligand/stem cell fac-
tor (SCF) and plays an essential role in the regulation of cell sur-
vival and proliferation, haematopoiesis, stem cell maintenance,
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gametogenesis, mast cell development, migration and function, and
melanogenesis [9, 10]. The inspiration to look for the presence of
KIT in the bladder came from functional gut research, where KIT+
ICC are well known to play central roles in pacemaking and signal
transduction [11]. KIT was first described in the bladder of guinea
pig by the group of McCloskey et al. [12] and has later also been
detected in rat [13], mouse [14], guinea pig [15] and human blad-
der [16].
The notion that KIT is expressed on IC in the bladder has been
challenged in recent years by several authors [6, 8, 17–20], who
presented evidence that KIT in the bladder might instead be
expressed by mast cells (known to be KIT+). This has led to a lively
debate on whether interspecies differences and antibody-related
issues might account for the discrepant findings of KIT expression
in the bladder. We have been working on bladder IC for many
years, and this ongoing debate inspired us to set up a comparative
study focussing on KIT expression in the bladder of different spe-
cies. The major aim of this study was to attempt to clarify the con-
flicting reports in the literature on KIT expression in the bladder
and to elucidate the possible role of antibody-related issues and
interspecies differences in this matter. To this end, we used solid
antibody controls and performed sound co-localization experiments,
which we believe are needed to provide robust, reproducible data
on KIT expression in the bladder.
Materials and methods
Tissue sampling and processing
The study protocol was in accordance with the EU guidelines and
approved by the institution’s ethical committees.
Human bladder tissue samples were obtained from cystectomies,
performed for invasive bladder cancer, without previous neo-adjuvant
treatment (intravesical or systemic). Samples from six cystectomies
(performed for bladder cancer, three females and three males) were
used and fully processed in this study. All cystectomy specimens were
received freshly from the operation room on dry ice and processed
within a time frame of 15 min. Bladders were opened from the anterior
side, and full thickness bladder wall biopsies were taken from the blad-
der dome, as far as possible from the macroscopically visible tumour.
Jejunum tissue samples (to serve as external positive antibody controls)
were obtained from the tissue database of the institutional pathology
department (KU Leuven).
Mice, rat and guinea pig bladder tissue were obtained from female
and male adult animals (12 weeks, n = 3/sex type). Strains were Spra-
gue Dawley rats, B6 mice and coloured BFA guinea pigs, housed in
cages with full access to food and water. Animals were killed by cervical
dislocation after isoflurane anaesthesia. Bladders were dissected, and
the bladder dome was cut into two halves. A part of the jejunum was
also dissected to use as external tissue control.
Table 1 Table listing the properties of the antibody clones used





(peptide corresponding to amino acids 963
to 976 at the cytoplasmic C-terminal part)




(peptide corresponding to amino acids
23-322 of human origin)
SC-5535 H-300 Santa Cruz Biotechnology,
Dallas, US
Rabbit h, m, r 1/100
MCT
(human beings, not further specified)
M7052 AA1 Dako, Glostrup, Denmark Mouse h Ready
to use
MCT
(peptide mapping within an internal region
of MCT of mouse origin)
SC-32474 G-12 Santa Cruz Biotechnology,
Dallas, US
Goat m, r 1/100
Vimentin
(synthetic peptide within human vimentin
amino acid 400 to the C-terminus (acetyl))
ab92547 EPR3776 Abcam, Cambridge, UK Rabbit h, m, r, 1/1000
Vimentin
(pig eye lens, not further specified)




(part of the C-terminus of the cytoplasmic
domain of the human DOG-1)





(Synthetic peptide of human
TMEM16A protein)
Ab53212 / Abcam, Cambridge, UK Rabbit h, m, r, gp 1/400
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All bladder samples were immediately fixed in formalin 6% and sub-
sequently embedded in paraffin. All biopsies were checked histologically
for the presence of normal bladder tissue.
Immunohistochemistry/immunofluorescence
Antibodies against KIT, mast cell tryptase (MCT), anoctamin-1 (ANO-1)
and vimentin were selected for their specificities to the epitopes of the
different species, as stated in the manufacturer’s data sheets and as
confirmed in the literature (Table 1). Some antibody clones showed
reliable immunoreactivity in control tissue of all species, while the
specificity of others was highly species-dependent.
Immunofluorescence labelling was performed on 5-lm sections. Sec-
tions were deparaffinized in xylene, followed by immersion in alcohol
and rehydration. Before staining, heat-induced epitope retrieval was per-
formed (30 min. at 120°C in Bond Epitope Retrieval Solution 2 (Leica
Biosystems, Belgium)). All stains consisted of a sequential approach:
sections were incubated with the first primary antibody for 30 min. at
room temperature, followed by the first secondary antibody during
30 min.; these steps were followed by the same cascade for the second
set of primary and secondary antibodies. Each step was followed by a
3 9 5 min. wash in Bond Wash Buffer (Leica Biosystems). Before each
incubation with primary antibody, slides were incubated with normal
goat serum (diluted 1:5 in PBS) for 30 min. to block non-specific epi-
topes. Nuclear counterstaining was performed with DAPI (300 nM in
PBS). Secondary antibodies were Alexa 568 Goat anti-mouse, Alexa 488
Goat anti-mouse, Alexa 568 Goat anti-rabbit and Alexa 488 Goat anti-
rabbit (Invitrogen, Life Technologies, Ghent, Belgium).
Images were collected with a Leica TCS SP5 laser scanning confocal
microscope (Leica Microsystems, Mannheim, Germany), using a HCX
PL APO 63.09 (NA:1.40) oil immersion lens. Different fluorochromes
were detected sequentially using excitation lines of 405 nm (DAPI, blue
colour), 488 nm (AlexaFluor488, green colour) or 561 nm (AlexaFluo-
r568, red colour). Emission was detected between 410–480 nm, 493–
555 nm and 566–630 nm, respectively. Overlap between red and green
signal of comparable intensity visually results in yellow signal on the
represented pictures.
Fig. 1 Upper panels: confocal immunofluorescence double staining for KIT (green) and MCT (red) showing co-occurrence of both antigens on mast
cells in the lamina propria and detrusor of human bladder (yellow arrows). Gut tissue is used as external tissue control, showing KIT+/MCT+ mast
cells (yellow arrows), with some KIT+/MCT mast cells (white arrows) in the tunica mucosa (TM). Lower panels: confocal immunofluorescence dou-
ble staining for KIT (green) and VIM (red) showing co-occurrence of both antigens on mast cells in the lamina propria and detrusor of human blad-
der (yellow arrows). White arrows indicate the many VIM+/KIT IC. Gut tissue is used as external tissue control, showing co-occurrence of both
antigens on ICC in the tunica muscularis externa (TME) (yellow arrows). White arrows indicate KIT/VIM+ IC. Bl, bladder; LP, lamina propria; D,
detrusor; TM, tunica mucosa; TME, tunica muscularis externa. DAPI blue stain illustrates nuclei. Scale bars: 25 lm.
ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
3
J. Cell. Mol. Med. Vol XX, No X, 2016
IHC stains were performed with the automated Leica Bond-Max sys-
tem (Leica Microsystems, Belgium). The automated procedure consisted
of blocking endogenous peroxidase activity using 0.3% H2O2 in
methanol, heat-induced antigen retrieval, incubation with primary anti-
bodies for 15 min., incubation with a peroxidase-labelled polymer dur-
ing 30 min. and a subsequent incubation with a substrate–chromogen
Fig. 2 Immunohistochemical stains for KIT on human bladder and gut with clones A4502 (upper panels) and SC-5535 (lower panels). In the bladder,
KIT is observed on mast cells (yellow arrows), while in the tunica muscularis externa (TME) of the gut, KIT is found on ICC with long cytoplasmic
processes (white arrows). The difference in morphology between these two cell types is remarkable. Both antibody clones show similar expression
patterns for KIT in the bladder and gut. Bl, bladder; U, urothelium; LP, lamina propria; D, detrusor; TME, tunica muscularis externa. Scale bars:
50 lm.
Fig. 3 Immunohistochemical stains for
MCT on the bladder in human beings (up-
per panels) and mouse and rat (lower
panels). In human bladder, MCT+ mast
cells are frequently observed, while in
mouse and rat bladder, mast cells are
sparse (yellow arrows). H, human; R, rat;
M, mouse; U, urothelium; LP, lamina pro-
pria; D, detrusor. Scale bars: 50 lm.
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(mixed DAB refine) for 10 min. Nuclear counterstaining was performed
with haematoxylin. Images were acquired using a Leica DM LB micro-
scope equipped with a DC300FX camera (Leica Microsystems).
Negative controls consisted of omission of the primary antibody,
resulting in absence of immunoreactivity. Positive controls consisted of
specific and expected IHC reaction on external control tissue (jejunum):
KIT positivity on ICC and mast cells, ANO-1 positivity on ICC and MCT
positivity on mast cells. Per species, bladder and jejunal tissue was
invariably processed on the same glass slide to ensure identical staining
conditions for target and control tissue.
Results
In human bladder, KIT was found on mast cells, but not on IC, as
shown by the immunofluorescence (IF) co-localization studies of KIT
with MCT (Fig. 1). This observation was consistent throughout all
bladder layers (LP and detrusor smooth muscle) and in all studied
biopsies. A double staining of KIT with the broad mesenchymal mar-
ker VIM revealed that the typical long-branched VIM-positive IC were
KIT (Fig. 1). Classic IHC stains for KIT and MCT showed similar dis-
tributions of both proteins on mast cells throughout the bladder wall
(Figs 2–3). Similar results were found with both KIT antibody clones
(A4502 and SC-5535) (Fig. 2). In the gut (jejunum), we observed
KIT+/MCT/VIM+ ICC in the tunica muscularis externa (TME) and
KIT+/MCT+ mast cells in the tunica mucosa (TM), which confirms the
specificity of the KIT antibody clones (Fig. 1). Classic IHC revealed a
similar KIT expression pattern on jejunal ICC in the TME (similar
results with both KIT antibody clones) (Fig. 2).
In rat and mouse bladder, KIT was only observed on mast cells,
which were occasionally present, and not on IC, as shown by the IF
co-localization of KIT with MCT (Figs 4–5). This observation was con-
sistent throughout all bladder layers and in all studied biopsies. More-
over, most studied rat and mouse bladder samples did not show any
mast cells at all. A double staining of KIT with VIM showed all long-
branched VIM+ IC to be KIT (Figs 4–5). Classic IHC stains for KIT
and MCT in bladder yielded similar findings (i.e. only sporadically
occurring mast cells showed co-localization) (Figs 3,6,7). In the jeju-
num, we observed KIT+/MCT/VIM+ ICC in the TME and KIT+/MCT+
Fig. 4 Upper panels: confocal immunofluorescence double staining for KIT (green) and MCT (red) showing co-occurrence of both antigens on a
mast cell in the detrusor of rat bladder (yellow arrow). Mast cells are very rare in rat bladder. Gut tissue is used as external tissue control, showing
KIT+/MCT+ mast cells (yellow arrows) in the tunica mucosa (TM). Lower panels: confocal immunofluorescence double staining for KIT (green) and
VIM (red) showing many VIM+/KIT IC (white arrows) in rat bladder. Gut tissue is used as external tissue control, with the presence of KIT+/VIM+
ICC (yellow arrows) and KIT/VIM+ IC (white arrow) in the tunica muscularis externa (TME). Bl, bladder; LP,lamina propria; D, detrusor; TM,tunica
mucosa; TME, tunica muscularis externa. DAPI blue stain illustrates nuclei. Scale bars: 25 lm.
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mast cells in the TM, which confirms the specificity of the KIT anti-
body clones (Figs 4–5). Classic IHC revealed a similar expression pat-
tern of KIT on jejunal ICC in the TME (Figs 6,7), with clone A4502
generating a better and finer distribution of ICC compared to clone
SC-5535.
In guinea pig bladder, we were unable to unequivocally confirm
that KIT+ cells are mast cells due to the lack of reliable MCT/KIT dou-
ble stains (we were unable to find decent MCT antibodies, to generate
acceptable staining). However, we observed similar expression pat-
terns for KIT as in other species, with only sparse KIT+ cells and with
large populations of long-branched VIM+/KIT IC in bladder LP and
detrusor (Fig. 8). Furthermore, the granular staining pattern of KIT is
compatible with mast cell origin. In gut tissue, we observed several
KIT+/VIM+ long-branched ICC in the TME (Fig. 8). Classic IHC stains
for KIT in bladder yielded similar findings (i.e. only sporadically
occurring mast cells in the LP and detrusor) (Fig. 8).
Classic IHC stains for the selective ICC marker ANO-1 did not
show any specific reaction in human, rat, mouse and guinea pig
bladder (Fig. 9). Parallel IHC stains for ANO-1 in human, rat, mouse
and guinea pig gut clearly illustrated many ICC in the TME (Fig. 10).
Discussion
KIT+ ICC have been studied in the gut for several decades, and there
is now scientific consensus that KIT+ ICC in gut are involved in gener-
ating pacemaking signals and in signal transduction [11, 21]. The dis-
covery of KIT+ cells in the bladder was therefore a promising finding
as it was assumed that these cells could have similar roles in the
onset of spontaneous bladder contractions and in the transmission of
electrical signals. In recent years, however, several authors have con-
tested the hypothesis that the KIT+ cells in bladder are indeed ICC as
seen in gut and instead argued that these cells could be mast cells [6,
8, 18–20] (which are also known to be KIT+). The present study pro-
vides ample evidence that KIT is expressed on mast cells and not on
IC in human, rat, mouse and guinea pig bladder.
Fig. 5 Upper panels: confocal immunofluorescence double staining for KIT (green) and MCT (red), showing no immunoreactive cells in mouse blad-
der. Mast cells are very rare in mouse bladder. Gut tissue is used as external tissue control, showing KIT+/MCT+ mast cells (yellow arrows) in the
tunica mucosa (TM). Lower panels: confocal immunofluorescence double staining for KIT (green) and VIM (red) showing many VIM+/KIT IC (white
arrows) in mouse bladder. Gut tissue is used as external tissue control, with the presence of KIT+/VIM+ ICC (yellow arrow) and KIT/VIM+ IC (white
arrow) in the tunica muscularis externa (TME). Bl, bladder; LP, lamina propria; D, detrusor; TM, tunica mucosa; TME, tunica muscularis externa.
DAPI blue stain illustrates nuclei. Scale bars: 25 lm.
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Several methodological issues might explain why KIT+ cells in the
bladder have been (erroneously) considered as ICC in previous stud-
ies. Antibody selection is a first essential step towards optimal IHC
results. Multiple comparative studies by the renowned IHC quality
platform Nordiqc have shown great variability in specificity and relia-
bility of different commercially available KIT antibody clones (www.
nordiqc.com). Nordiqc recommends the A4502 clone used in the pre-
sent study as one of the two preferential antibodies for the detection
of KIT in human clinical diagnostics (www.nordiqc.org/Run-26-B7/
Assessment/assessment-26-CD117). The use of one of the several
other commercially available KIT antibody clones might have resulted
in less specific reaction patterns. Antibody controls are a second key
element for reliable IHC results, and one of the most rigorous anti-
body controls is the positive anatomical control, that is where the
presence of the antigen in the specimen is known a priori and is not
the target of the experimental treatment [22, 23]. For KIT, gut tissue
Fig. 6 Immunohistochemical stains for KIT
on rat bladder and gut with clones A4502
(upper panels) and SC-5535 (lower pan-
els). In the bladder, almost no KIT+ mast
cells are observed, while in the gut, KIT is
found on mast cells (yellow arrows) and
ICC with long cytoplasmic processes
(white arrows). Both antibody clones
show similar expression patterns for KIT
in the bladder and gut. Bl, bladder; U,
urothelium; LP, lamina propria; D, detru-
sor; TME, tunica muscularis externa; TM,
tunica mucosa. Scale bars: 50 lm.
Fig. 7 Immunohistochemical stains for KIT
on mouse bladder and gut with clones
A4502 (upper panels) and SC-5535 (lower
panels). In the bladder, almost no KIT+
mast cells are observed, while in the gut,
KIT is found on mast cells (yellow arrows)
and ICC with long cytoplasmic processes
(white arrows). Both antibody clones
show similar expression patterns for KIT
in the bladder and gut. Bl: bladder, U:
urothelium, LP: lamina propria, D: detru-
sor, TME: tunica muscularis externa, TM:
tunica mucosa. Scale bars: 50 lm.
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serves as an excellent positive antibody control, due to the well-estab-
lished presence of KIT+ ICC [24, 25]. In this study, the specificity of
the KIT antibodies was specifically validated by parallel staining of gut
tissue on the same glass slide, which typically yielded KIT+ ICC (as
further confirmed with double stains) and KIT+ mast cells. We did not
find reports of the use of positive anatomical controls in literature on
KIT expression in bladder [7, 12–16, 26, 27] (see also Table 2), pos-
sibly explained by the recent nature of these evolutions in IHC quality
control protocols [22, 23]. A third essential methodological parameter
to reliably determine KIT expression in the bladder relates to the use
of double stains. KIT is known to be expressed on several other cell
types apart from ICC, that is mast cells, hematopoietic cells, sper-
matogonia and melanocytic cells [21]. Of these populations, only
mast cells are known to be expressed in the bladder, which is why we
performed double stains with MCT in an attempt to rule out the possi-
bility of a KIT+ mast cell population. KIT+ mast cells might have been
wrongly interpreted as ICC due to the often similar morphological
appearance of both cell types and the lack of reliable MCT/KIT double
stains. The higher number of mast cells in human bladder compared
to laboratory animals is remarkable, but might be explained by an
inevitable selection bias: human bladder samples are likely to have at
least some degree of inflammation (as reflected by a higher number
of mast cells) as human cystectomies are, by definition, performed in
a pathological setting, while cystectomies on animals can be per-
formed under well-controlled conditions without any relevant inflam-
mation. In guinea pig bladder, we were unable to perform decent
MCT/KIT double stains, due to the absence of reliable commercially
available MCT antibodies. Most publications reporting on KIT+ ICC in
bladder did not perform MCT/KIT double stains, with no reports of
MCT/KIT double stains in guinea pig bladder [7, 12, 13, 15, 16, 27]
(for an overview, see also Table 2).
Another important element was the absence of expression of the
ICC-selective marker ANO-1 [28] (also known as DOG1 or TMEM16A)
in human, rat, mouse and guinea pig bladder, which further favours
the absence of typical ICC in bladder (ANO1-IHC was validated by
presence of ANO1+ ICC in gut). Several authors also reported on the
absence of the typical ultrastructural ICC characteristics in IC in the
bladder, lending additional evidence for another phenotype for these
cells [8, 18, 19]. We know from previous work that IC in the bladder
constitute a complex cell family including fibroblasts, myofibroblasts,
ICC-like cells and telocytes, with different IC phenotypes in the lamina
propria versus the detrusor [8, 18, 19]. At present, our knowledge of
Fig. 8 Upper panels: confocal immunofluorescence double staining for VIM (green) and KIT (red) showing co-occurrence of both antigens on mast
cells in the lamina propria and detrusor of guinea pig bladder (yellow arrows). White arrows indicate the many VIM+/KIT IC. Gut tissue is used as
external tissue control, showing co-occurrence of both antigens on ICC in the tunica muscularis externa (TME) (yellow arrows). White arrows indi-
cate KIT/VIM+ IC. Scale bars equal 25 lm. Lower panels: immunohistochemical stains for KIT on guinea pig bladder and gut with clone A4502. In
the bladder, KIT is observed on mast cells (yellow arrows), while in the tunica muscularis externa (TME) of the gut, KIT is found on mast cells (yel-
low arrows) and ICC with long cytoplasmic processes (white arrows). Mast cells are rare in guinea pig bladder. The difference in morphology
between these two cell types is remarkable. Scale bars equal 50 lm. Bl: bladder, U: urothelium, LP: lamina propria, D: detrusor, TME: tunica mus-
cularis externa, TM: tunica mucosa.
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IC in the bladder is rather limited, which is partially explained by the
lack of specific cell markers, needed to selectively target these cells.
As KIT has long been assumed to be present on bladder IC, several
groups have tried to study the role of KIT+ IC in bladder physiology by
blocking the KIT receptor with the KIT inhibitor imatinib mesylate (IM).
Acute administration of IM caused decreased contractility in guinea
pig and human bladder [29], while chronic administration of IM in
neonatal rats resulted in impaired development of networks of inter-
muscular IC [5]. Considering that IM also blocks PDGFRa [30], a
receptor widely expressed on bladder IC [7, 20], we think that the
effects of IM on bladder contractility and IC development might be
explained via the PDGFRa pathway.
Fig. 10 Immunohistochemical stains for
ANO1 on human, rat, mouse and guinea
pig gut. In all species, many ANO1+ ICC
are seen in the TME (yellow arrows).
TME: tunica muscularis externa, TM:
tunica mucosa. Scale bars: 50 lm.
Fig. 9 Immunohistochemical stains for ANO1 on human, rat, mouse and guinea pig bladder. No immunoreactivity was observed. U: urothelium, LP:
lamina propria, D: detrusor. Scale bars: 50 lm.
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Conclusions
In conclusion, we have shown that KIT+ cells in human, rat, mouse
and guinea pig bladder are mast cells and not ICC. The present report
is important as it opposes the idea that KIT+ ICC are present in blad-
der. In this perspective, functional concepts of KIT+ ICC being
involved in sensory and/or motor aspects of bladder physiology
should be revised. One of the major challenges in IC research will be
to search for specific cell markers to investigate these cells more
selectively.
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